Back
The exerkine apelin reverses age-associated sarcopenia.
Journal article

The exerkine apelin reverses age-associated sarcopenia.

  • Vinel C Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Lukjanenko L Aging Department, Nestlé Institute of Health Sciences SA, Ecole Polytechnique Fédérale de Lausanne Innovation Park, Lausanne, Switzerland.
  • Batut A Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Deleruyelle S Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Pradère JP Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Le Gonidec S Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Dortignac A Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Geoffre N Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Pereira O Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Karaz S Aging Department, Nestlé Institute of Health Sciences SA, Ecole Polytechnique Fédérale de Lausanne Innovation Park, Lausanne, Switzerland.
  • Lee U Aging Department, Nestlé Institute of Health Sciences SA, Ecole Polytechnique Fédérale de Lausanne Innovation Park, Lausanne, Switzerland.
  • Camus M Institut de Pharmacologie et de Biologie Structurale-CNRS, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Chaoui K Institut de Pharmacologie et de Biologie Structurale-CNRS, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Mouisel E Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Bigot A Institut de Myologie, Université Pierre et Marie Curie, Paris 6 UM76, Univ. Paris 6/U974, UMR7215, CNRS, Pitié-Salpétrière-INSERM, UMRS 974, Paris, France.
  • Mouly V Institut de Myologie, Université Pierre et Marie Curie, Paris 6 UM76, Univ. Paris 6/U974, UMR7215, CNRS, Pitié-Salpétrière-INSERM, UMRS 974, Paris, France.
  • Vigneau M Institut des Technologies Avancées en Science du Vivant-USR3505 Centre Pierre Potier, Toulouse, France.
  • Pagano AF Université de Montpellier, Institut National de la Recherche Agronomique, UMR866 Dynamique Musculaire et Métabolisme, Montpellier, France.
  • Chopard A Université de Montpellier, Institut National de la Recherche Agronomique, UMR866 Dynamique Musculaire et Métabolisme, Montpellier, France.
  • Pillard F Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Guyonnet S Gérontopole Toulouse-Purpan UMR 1027, Toulouse, France.
  • Cesari M Gérontopole Toulouse-Purpan UMR 1027, Toulouse, France.
  • Burlet-Schiltz O Institut de Pharmacologie et de Biologie Structurale-CNRS, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Pahor M Institute on Aging, College of Medicine, University of Florida, Gainesville, FL, USA.
  • Feige JN Aging Department, Nestlé Institute of Health Sciences SA, Ecole Polytechnique Fédérale de Lausanne Innovation Park, Lausanne, Switzerland.
  • Vellas B Gérontopole Toulouse-Purpan UMR 1027, Toulouse, France.
  • Valet P Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Dray C Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Université de Toulouse, Université Paul Sabatier, Toulouse, France. cedric.dray@inserm.fr.
Show more…
  • 2018-08-01
Published in:
  • Nature medicine. - 2018
Adenylate Kinase
Adolescent
Adult
Aged
Aged, 80 and over
Aging
Animals
Apelin
Apelin Receptors
Body Weight
Exercise
Humans
Kinetics
Mice, Inbred C57BL
Muscle Cells
Muscle Weakness
Muscle, Skeletal
Organelle Biogenesis
Protein Biosynthesis
Proto-Oncogene Proteins c-akt
Regeneration
Ribosomal Protein S6 Kinases, 70-kDa
Sarcopenia
Satellite Cells, Skeletal Muscle
English Sarcopenia, the degenerative loss of skeletal muscle mass, quality and strength, lacks early diagnostic tools and new therapeutic strategies to prevent the frailty-to-disability transition often responsible for the medical institutionalization of elderly individuals. Herein we report that production of the endogenous peptide apelin, induced by muscle contraction, is reduced in an age-dependent manner in humans and rodents and is positively associated with the beneficial effects of exercise in older persons. Mice deficient in either apelin or its receptor (APLNR) presented dramatic alterations in muscle function with increasing age. Various strategies that restored apelin signaling during aging further demonstrated that this peptide considerably enhanced muscle function by triggering mitochondriogenesis, autophagy and anti-inflammatory pathways in myofibers as well as enhancing the regenerative capacity by targeting muscle stem cells. Taken together, these findings revealed positive regulatory feedback between physical activity, apelin and muscle function and identified apelin both as a tool for diagnosis of early sarcopenia and as the target of an innovative pharmacological strategy to prevent age-associated muscle weakness and restore physical autonomy.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/16441
Statistics
Document views: 13 File downloads: